tPA by Endovascular Administration for the Treatment of Submassive PE Using CDT for the Reduction of Thrombus Burden
Public ClinicalTrials.gov record NCT04248868. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Recombinant tPA by Endovascular Administration for the Treatment of Submassive Pulmonary Embolism Using Pharmaco-mechanical Catheter Directed Thrombolysis for the redUction of Thrombus burdEn
Study identification
- NCT ID
- NCT04248868
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Thrombolex, Inc.
- Industry
- Enrollment
- 109 participants
Conditions and interventions
Conditions
Interventions
- The Bashir™ Endovascular Catheter Device
- r-tPA Drug
Device · Drug
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 22, 2020
- Primary completion
- Jun 21, 2022
- Completion
- Jun 22, 2022
- Last update posted
- Apr 19, 2023
2020 – 2022
United States locations
- U.S. sites
- 19
- U.S. states
- 13
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UCLA | Los Angeles | California | 90095 | — |
| Miami Cardiac & Vascular Institute | Miami | Florida | 33176 | — |
| Advent Health Orlando | Orlando | Florida | 32803 | — |
| Emory | Atlanta | Georgia | 30308 | — |
| Piedmont Heart Institute | Atlanta | Georgia | 30309 | — |
| Loyola University Chicago | Maywood | Illinois | 60521 | — |
| Ascension St. Vincent | Indianapolis | Indiana | 46260 | — |
| Ascension St. John Hospital | Detroit | Michigan | 48201 | — |
| Beaumont Hospital, Royal Oak | Royal Oak | Michigan | 48073 | — |
| University of Minnesota | Minneapolis | Minnesota | 55455 | — |
| St. Joseph's Hospital | Liverpool | New York | 13088 | — |
| NYU Langone | New York | New York | 10016 | — |
| NC Heart | Raleigh | North Carolina | 27607 | — |
| Mt Carmel | Columbus | Ohio | 43213 | — |
| UPMC Hamot | Erie | Pennsylvania | 16550 | — |
| Temple University Hospital | Philadelphia | Pennsylvania | 19122 | — |
| UPMC Heart and Vascular Institute | Pittsburgh | Pennsylvania | 15232 | — |
| Tennova Heart - Turkey Creek | Knoxville | Tennessee | 37934 | — |
| CAMC | Charleston | West Virginia | 25304 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04248868, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 19, 2023 · Synced Jun 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04248868 live on ClinicalTrials.gov.